S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML

S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML

Bibliographic Details
Main Authors:	H. Erba, P. Montesinos, R. Vrhovac, E. Patkowska, H.-J. Kim, P. Zak, P.-N. Wang, T. Mitov, J. Hanyok, L. Liu, A. Benzohra, A. Lesegretain, J. Cortes, A. Perl, M. Sekeres, H. Dombret, S. Amadori, J. Wang, M. Levis, R. Schlenk
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843296.73803.85

Similar Items

S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST
by: Richard Schlenk, et al.
Published: (2023-08-01)

P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL
by: Mark J Levis, et al.
Published: (2023-08-01)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
by: Mar Tormo, et al.
Published: (2023-08-01)

S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY
by: M. Yilmaz, et al.
Published: (2022-06-01)

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
by: Sonia Jaramillo, et al.
Published: (2023-09-01)

Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy
by: Samuel J. Taylor, et al.
Published: (2017-11-01)

S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
by: Pau Montesinos, et al.
Published: (2023-08-01)

<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
by: Andrew Y. Li, et al.
Published: (2021-03-01)

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation.
by: Kharazi, S, et al.
Published: (2011)

P569: GILTERITINIB AND QUIZARTINIB IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOBLASTIC LEUKEMIA (AML) WITH FLT3 MUTATIONS: A REAL-LIFE EFFECTIVENESS AND SAFETY STUDY
by: D. Quintela, et al.
Published: (2022-06-01)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
by: R. Iannotta, et al.
Published: (2022-01-01)

The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors
by: Yang Qiu, et al.
Published: (2023-02-01)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
by: Tobias R. Haage, et al.
Published: (2023-05-01)

ROLE OF BIALLELIC C/EBPALPHA MUTATIONS AND FLT-3 ITD IN INITIATION AND MAINTENANCE OF AML
by: Reckzeh, K, et al.
Published: (2010)

FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.
by: Mead, A, et al.
Published: (2013)

FLT3-ITDs Introduce a Myeloid Differentiation and Transformation Bias to Multipotent Lympho-Myeloid Progenitors
by: Mead, A, et al.
Published: (2011)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
by: Dan Xu, et al.
Published: (2022-07-01)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
by: Maximilian Fleischmann, et al.
Published: (2021-11-01)

Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations
by: Shaina N Porter, et al.
Published: (2016-11-01)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
by: D Sorcini, et al.
Published: (2023-11-01)

Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
by: Katharina Sies, et al.
Published: (2019-04-01)

Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD
by: Julhash U. Kazi, et al.
Published: (2023-11-01)

FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia
by: Mariko Takenokuchi, et al.
Published: (2012-10-01)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
by: Mark C Weir, et al.
Published: (2017-01-01)

Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1
by: Daniel J.L. Coleman, et al.
Published: (2024-04-01)

FLT3-ITD INDUCED MYELOPROLIFERATION CAUSES A CELL EXTRINSIC DEPLETION OF HAEMATOPOIETIC STEM CELLS
by: Mead, A, et al.
Published: (2014)

AD80 HAS HIGHER POTENCY COMPARED TO CLINICALLY USED FLT3 INHIBITORS IN FLT3-ITD AML CELLS
by: LBL Miranda, et al.
Published: (2023-10-01)

Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD–induced myeloproliferation
by: Mead, A, et al.
Published: (2017)

Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction
by: Sara Latini, et al.
Published: (2024-04-01)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
by: Shano Naseem, et al.
Published: (2021-01-01)

FLT3 - ITD positive acute lymphocytic leukemia, does it impact on disease´s course?
by: Sebastian Kobold, et al.
Published: (2010-06-01)

FLT3 - ITD positive acute lymphocytic leukemia, does it impact on disease´s course?
by: Sebastian Kobold, et al.
Published: (2010-06-01)

HSP70 and FLT3-ITD: Targeting chaperone system to overcome drug resistance
by: Jing Yang, et al.
Published: (2021-10-01)

Disrupting PTPRJ transmembrane-mediated oligomerization counteracts oncogenic receptor tyrosine kinase FLT3 ITD
by: Marie Schwarz, et al.
Published: (2022-11-01)

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
by: Fangmin Huang, et al.
Published: (2023-09-01)

Data-Driven Math Model of FLT3-ITD Acute Myeloid Leukemia Reveals Potential Therapeutic Targets
by: David J. Wooten, et al.
Published: (2021-03-01)

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
by: Xinhua Xiao, et al.
Published: (2023-11-01)

P406: ENHANCED SIGNIFICANCE OF FLT3-ITD RESIDUAL DISEASE DETECTION ON TREATMENT OUTCOME IN ACUTE MYELOID LEUKEMIA
by: T. Grob, et al.
Published: (2022-06-01)

Maturation State-Specific Alternative Splicing in <i>FLT3</i>-ITD and NPM1 Mutated AML
by: Anna Wojtuszkiewicz, et al.
Published: (2021-08-01)

Eccentricity of Acute Myeloid Leukemia with NPM1 and FLT3-ITD mutation: a case report
by: Nur Zainura Mohamad,, et al.
Published: (2022)